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Both genetic and epigenetic alterations characterize human nonsmall cell lung cancer (NSCLC), but the biological processes that
create or select these alterations remain incompletely investigated. Our hypothesis posits that a roughly reciprocal relationship
between the propensity for promoter hypermethylation and a propensity for genetic deletion leads to distinct molecular
phenotypes of lung cancer. To test this hypothesis, we examined promoter hypermethylation of 17 tumor suppressor genes,
as a marker of epigenetic alteration propensity, and deletion events at the 3p21 region, as a marker of genetic alteration. To
model the complex biology between these somatic alterations, we utilized an item response theory model. We demonstrated
that tumors exhibiting LOH at greater than 30% of informative alleles in the 3p21 region have a signiﬁcantly reduced propensity
for hypermethylation. At the same time, tumors with activating KRAS mutations showed a signiﬁcantly increased propensity for
hypermethylation of the loci examined, aresult similar towhat has been observed in colon cancer. These data suggest that NSCLCs
have distinct epigenetic or genetic alteration phenotypes acting upon tumor suppressor genes and that mutation of oncogenic
growth promoting genes, such as KRAS, is associated with the epigenetic phenotype.
Copyright © 2008 Carmen J. Marsit et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Lung cancer remains one of the most incident cancers and
the leading cause of cancer death in both men and women
in the United States. In 2006, there were over 162000 deaths
attributable to lung cancer in the U.S. [1]. The major cause
of lung cancer is tobacco smoking, although environmental
tobacco smoke, asbestos, and other environmental and
industrial exposures also contribute to lung carcinogenesis
[2]. Nonsmall cell lung cancer (NSCLC) is derived from the
epithelial cells of the lung and bronchus and is characterized
by a wide variety of molecular alterations. Included among
these are activating mutations in oncogenes (such as cMYC,
KRAS, EGFR, CCND1, and BCL2) and inactivating lesions
in tumor suppressor genes [3, 4]. The inactivation of tumor
suppressor genes occurs chieﬂy through allele loss (both sin-
gle allele loss and homozygous gene deletion) or epigenetic
silencingassociatedwithpromoterhypermethylationofCpG
islands in the promoters of many of these genes [5–7].
The relationship between these various genetic and
epigenetic alterations has remained relatively unexplored,
although it is now known that there is a surprisingly large
number of genetic alterations evident in solid tumors [8].
An u m b e ro fg r o u p sh a v er e p o r t e dt h a ta l t e r a t i o n st oT P 5 3 ,
measured both as mutation of the gene or through altered
immunohistochemical staining, are associated with greater
prevalence of LOH at various loci [9–11]. There have also
been links made between lung carcinogen exposures and
several genetic alterations. For example, LOH of the FHIT
gene is found more often in smokers and those exposed2 Journal of Cancer Epidemiology
to asbestos in an occupational setting [12, 13]. Work from
our group and others has also suggested that carcinogen
exposures may drive the type of alterations observed in
speciﬁc genes, such as CDKN2A (encoding P16INK4A),
which is more often deleted in never smoking individuals
[14] but has an increasing prevalence of hypermethylation
with increasing duration of tobacco smoking [15, 16].
Likewise, mutation of the EGFR gene occurs speciﬁcally
in adenocarcinomas, and most often in women and never
smoking patients [17–20]. This type of evidence reveals
that distinct molecular phenotypes exist in NSCLC and
that exposure, lifestyle, or a combination of these factors
drive these phenotypes. Better deﬁnition of the number and
character of these phenotypes may be critical for making
clinical decisions about treatment course for patients, as
has been evidenced in the EGFR mutation case [21–24].
Thus, this study was aimed at better deﬁning the molecular
phenotypes in NSCLC, closely examining the relationship
between genetic and epigenetic alterations in this disease.
2. SUBJECTS AND METHODS
2.1. Studypopulation
Eligible cases consisted of all newly diagnosed patients
with resectable lung cancer who received treatment at the
MassachusettsGeneralHospitalThoracicSurgery,Oncology,
and Pulmonary Services from November 1992 through
December 1996 [25]. The patients involved in these stud-
ies provided written informed consent under a protocol
approved by the appropriate Institutional Review Boards.
Patients with recurrent disease or nonoperable tumors were
excluded. A random subset of 260 was analyzed for somatic
loss (LOH) at 3p21. A subset of 185 patients of the parent
study had fresh lung tumor tissue obtained for use in
hypermethylation analysis. Tumor tissue was snap frozen
in liquid nitrogen and stored at −80
◦C until processed.
Demographic and epidemiological data, including all of the
data on tobacco use, were gathered by interviewer review of
a self-administered questionnaire completed by patients and
reviewed by a single reviewer during the hospitalization for
thoracic surgery.
2.2. 3p21LOHanalysis
Analysis of allelic loss at the 3p21 region at microsatellite
markers D3S1029, D3S3582, D3S3667, D3S3640, D3S1568,
and D3S3026,a n dD3S1478 and the details of the statistical
analysis and construction of the fraction allele loss (FAL)
score have been previously described for this population
[9, 26].
2.3. Hypermethylationanalysis
DNA was extracted from fresh frozen tumor tissue using the
Gentra Puregene DNA extraction kit (Gentra, Minneapolis,
Minn, USA) following manufacturer’s protocol. Sodium
bisulﬁte modiﬁcation of the resultant DNA was performed
as previously described [27]. Brieﬂy, DNA was denatured in
NaOH and treated with sodium bisulﬁte (Sigma Chemical
Co., St. Louis, Miss, USA) for 16 hours. The DNA was
then puriﬁed using a Wizard DNA Clean-Up Kit (Promega,
Madison, Wiss, USA),treated again with NaOH, and ethanol
precipitated. DNA was rehydrated in water for subsequent
use in PCR ampliﬁcation.
We have speciﬁcally chosen to utilize traditional methy-
lation speciﬁc PCR (MSP) [27] for the analysis of promoter
hypermethylation in these studies. We have previously
examinedpotentialbiasesinthesensitivityofusingthisassay
against the relative-quantitative Taqman-based methods
[28], and have seen no evidence for potential bias based on
tumor quantity or tumor stage in the samples analyzed.
Sodium bisulﬁte modiﬁed DNA was used as the template
for methylation speciﬁc PCR (MSP) as previously described
in [27] using primers speciﬁc for the methylated promoters
of CDKN2A [27], RASSF1A [29], APC [30], PYCARD
[31], LAMC2 [32], SFRP1, SFRP2, SFRP4, SFRP5 [33],
MGMT, DAPK, RARB, CDH1 [34], CDH13 [35], MLH1
[36], CCND2 [37], and PRSS3 [38]. All methylation speciﬁc
PCRs are optimized to detect greater than 5% methylated
substrate in each sample. To control for the presence of
modiﬁed DNA, primers speciﬁc to a modiﬁed region of
the ACTB gene containing no CpG sites were used [39].
ModiﬁedcirculatingbloodlymphocyteDNA(obtainedfrom
a controlsubject) and the same lymphocyte DNA completely
methylated using SssI DNA methylase and modiﬁed by
treatmentwithsodiumbisulﬁtewereusedasthenegativeand
positive controls, respectively, in each run.
These genes were chosen as promoter hypermethylation
detected using this method has been previously shown to
be correlated to transcriptional silencing of these genes, and
their hypermethylation occurs in a tumor-speciﬁc pattern.
We also wished to examine the silencing of tumor suppressor
genes involved in a variety of cellular processes and pathways
thereby not limiting the analysis to genes involved in a
single pathway targeted for inaction. The genes selected
are known to be involved in processes including cell cycle
control (CDKN2A, RASSF1A, APC, and CCND2), apopto-
sis (DAPK, PYCARD), extracellular interactions (LAMC2,
PRSS3), transcriptional regulation (RARB), WNT signaling
(SFRP family),cell-cellsignaling(CDH1,CDH13),andDNA
repair (MGMT, MLH1).
2.4. Statisticalanalysis
We have previously demonstrated that there are no discreet
groupings of tumors by the number of genes undergoing
hypermethylation [5] and we have observed that there is a
great deal of correlation between methylation of the individ-
ualloci,suchthatsimplycountingthenumberofmethylated
loci in an individual tumor is statistically inappropriate.
Therefore, we employed an item response theory (IRT)
model[40]whichhasbeenshowntobethemostappropriate
latent trait technique [41] for examining this type of discrete
data [42] and which allows the modeling of the propensity
for methylation to be treated as a continuous variable in a
regression framework.Carmen J. Marsit et al. 3
To construct our IRT model, we used a stepwise selection
combined with domain knowledge examining the eﬀect of
exposuresonthelatentmethylationvariable.Ageandgender
are included in the model as there have been reports of age-
related methylation [43, 44], and there is a well-established
diﬀerence in the prevalence of bladder cancer by gender.
Histology (adenocarcinoma, squamous cell carcinoma, and
others) was initially included in the model. We examined
the eﬀects of exposures which have been demonstrated to
be associated with lung cancer incidence including cigarette
smoking and occupational asbestos exposure. Cigarette
smoking was examined as a variable comparing never,
former, and current smokers as well as using measures
of duration and intensity. We also examined the eﬀect of
mutation of the KRAS gene which has been previously
reported in this population of tumors [25, 45], as mutation
of this pathway is associated with a methylator phenotype
in colon cancer [46]. As a marker of genetic alteration,
we included the FAL score of 3p21 LOH. Variables were
excluded from the model by using the AIC to determine the
most parsimonious model. The ﬁnal model included gender,
KRAS mutation, and 3p21 FAL (low ≤0.3 versus high >0.3)
as covariates in addition to the promoter hypermethylation
status of the 17 genes was examined.
We also examined the associations between propensity
for hypermethylation, again characterized by the methyla-
tion latent trait, and patient survival. In a second stage
analysis, we used the predictions of the methylation latent
trait and employed a Cox proportional hazards model to
examine the logarithm of the hazard of death as a linear
function of covariates, including the methylation latent trait.
AllanalyseswereconductedinRversion2.4.1[47],including
custom software for the IRT model, available upon request.
3. RESULTS
The demographics of the study population are shown in
Table 1. As expected, the majority of patients were either
currentorformersmokers,withameanageofapproximately
67 years. Greater than 50% of the tumors were adenocar-
cinomas, with about 34% squamous cell carcinoma, and
the remaining of the rarer histologies such as large cell.
As previously noted, approximately 17% of the cases had
mutation of KRAS at codon 12 [45], the hotspot for lung
cancer, and about 34% had loss of heterozygosity (LOH) at
greater than 30% of informative alleles in the 3p21 region
[9].
Figure 1(a) presents the prevalence of hypermethylation
of the 17 gene promoters examined in this study. The
prevalence of this alteration appears highly variable by the
gene examined, with some genes, such as SFRP1 and SFRP2
found to be hypermethylated in nearly 80% of cases, while
other genes, such as MLH1 or APC, rarely exhibiting hyper-
methylation in this series. There was moderate correlation
between methylation at the individual loci, as depicted
in Figure 1(b), where lighter shades represent correlation
coeﬃcients approaching 1. As we observed, this relatively
high correlation between methylation events, and the broad
range of prevalence of these alterations at diﬀerent genes,
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Figure 1: Prevalence and correlation between promoter hyper-
methylation at 17 genes in NSCLC. (a) Bar graph representing
the prevalence of promoter hypermethylation at various gene
promotersexaminedin177NSCLCtumors.(b)Heatmapdepicting
the correlation coeﬃcient (as depicted in the gradient bar) between
individual promoter hypermethylation of 17 genes examined in
NSCLC.
rather than treat these events as independent in the analysis,
we employed an item response theory model to investigate
the propensity for hypermethylation in these tumors. This
approach takes into account this correlation and has been
showntobeappropriateforsimilardataexaminedinbladder
cancer [42].
The results of the item response model are listed in
Table 2, which provides the coeﬃcient values of the slopes
and intercepts for each of the genes examined in this
series. Although the values of the intercepts are not directly
interpretable, they are provided for completeness as they are
used in plotting the relationship between the latent trait and4 Journal of Cancer Epidemiology
Table 1: Demographics of the NSCLC case series.
Characteristic
Age, mean (SD) 66.9(10.6)
Gender,n( p r e v a l e n c e )
Female 80(0.45)
Male 97(0.55)
Histology,n( p r e v a l e n c e )
Adenocarcinoma 95(0.54)
Adeno-squamous 5(0.03)
Bronchoalveolar 2(0.01)
Large cell 14(0.08)
Squamous cell 61(0.34)
Tumor TNM stage,n( p r e v a l e n c e )
Stage 1 99(0.56)
Stage 2 34(0.19)
Stage 3 39(0.22)
Stage 4 5(0.03)
Smoking status,n( p r e v a l e n c e )
Never 13(0.07)
Former 93(0.52)
Current 71(0.40)
KRAS codon 12 mutation,n( p r e v a l e n c e )
No 147(0.83)
Yes 30(0.17)
3p21 LOH fraction allelic loss score, n( p r e v a l e n c e )
∗
0–0.3 100(0.66)
>0.3 52(0.34)
∗3p21 LOH data not available for 25 samples.
the probability of methylation. The slope, on the other hand,
indicates the strength of the relationship between the latent
trait and probability of methylation of the gene. The range
of values for the slope terms of these genes suggests that
genes contribute diﬀerentially to the modeled underlying
propensity for methylation. Comparisons with the overall
prevalence demonstrate that the model is not solely driven
by prevalence, as genes with relative high prevalence, such
as RASSF1A, which are methylated in approximately 50%
of cases, in fact have a nonsigniﬁcant and negative item
response slope, while CCND2 (encoding Cyclin-D2), with
a prevalence of methylation of approximately 30%, has a
highly signiﬁcant slope of 1.3.
This model also examined the impact of exposures,
demographics, tumor characteristics, and other molecular
alterations onthe underlying propensity formethylation. We
found that only KRAS mutation status and fraction allelic
loss score of LOH at 3p21 were signiﬁcantly associated with
the propensity for hypermethylation. Gender was kept in the
model as it is a known confounder of KRAS mutation status
[25]. Having mutation of KRAS leads to an approximately
0.5 unit increase in latent trait mean (where latent trait is
scaled to have unit standard deviation) (P<. 05). On the
other hand, having a 3p21 LOH fraction allele loss score of
>0.3, indicating that greater than 30% of informative loci
examined in the region demonstrated LOH, was associated
with a statistically signiﬁcant reduction by 0.5 unit in the
methylation latent trait mean (P<. 02). We found no
signiﬁcant association between overall patient survival and
the methylation latent trait in a second stage analysis.
4. DISCUSSION
TheexistenceofaCpGislandmethylatorphenotype(CIMP)
has been demonstrated in a number of tumor types, most
conclusively in colorectal, and gastric cancers [44, 48–
50]. In colon cancer, the CIMP phenotype is associated
with genetic mutation of the BRAF gene, and it has also
been suggested that this phenotype, particularly through its
associated methylation of the MLH1 gene, is responsible
for mismatch repair deﬁciency and thus the microsatellite
instability observed in a subset of colorectal cancers [46].
Mutation of the KRAS gene has also been associated with
CIMP in colorectal cancer [48, 50]. Our recent work
has also suggested that tumors from a number of other
sites, including the lung, may exhibit diﬀerences in their
underlying propensity for hypermethylation [5]. Assessment
of the methylator phenotype in lung cancer is complicated
by a lack of understanding as to which genes should be
assessed to determine this phenotype, as those used in colonCarmen J. Marsit et al. 5
Table 2: Item response model for NSCLC promoter hypermethyla-
tion and covariates.
Est SE P
Item response intercepts
DAPK −1.10 0.22 <.0001
RASSF1A −0.20 0.17 .24
CDKN2A −0.84 0.18 <.0001
MGMT −0.66 0.27 .02
RARB 0.82 0.28 .004
SFRP1 2.24 0.42 <.0001
SFRP2 2.80 0.51 <.0001
SFRP4 −0.86 0.28 .002
SFRP5 1.67 0.42 .0001
CDH1 0.88 0.36 .01
APC −1.83 0.25 <.0001
PYCARD −2.99 0.42 <.0001
LAMAC2 −0.38 0.40 .35
CDH13 0.03 0.24 .90
MLH1 −3.77 0.57 <.0001
CCND2 −0.90 0.32 .006
PRSS3 0.20 0.19 .30
Item response slopes
DAPK 0.50 0.24 .04
RASSF1 −0.16 0.17 .33
CDKN2A 0.11 0.19 .56
MGMT 1.02 0.26 .0001
RARB 0.98 0.24 <.0001
SFRP1 1.70 0.29 <.0001
SFRP2 1.68 0.35 <.0001
SFRP4 0.99 0.26 .0002
SFRP5 1.67 0.27 <.0001
CDH1 1.43 0.28 <.0001
APC 0.15 0.22 .50
PYCARD 0.61 0.25 .01
LAMAC2 1.82 0.27 <.0001
CDH13 0.84 0.24 .0005
MLH1 0.14 0.40 .72
CCND2 1.32 0.28 <.0001
PRSS3 0.43 0.19 .02
Latent trait mean eﬀects
Gender
Male Referent
Female −0.34 0.22 .11
KRAS codon 12 mutation
No mutation Referent
Mutation 0.54 0.28 .05
3p21 LOH FAL score
0–0.3 Referent
>0.3 −0.56 0.24 .02
cancers may not be appropriate. Thus, we have sought to
more thoroughly examine what factors may be driving this
propensity, and if there are speciﬁc molecular phenotypes
extant in NSCLC.
As we previously demonstrated, there are no discreet
groupings of tumors by the number of genes undergoing
hypermethylation [5],aﬁndingthathasledsometoquestion
the existence of a methylator phenotype [51]. We have also
shown (Figure 1(b)) that there is a great deal of correlation
between methylation of the individual loci, such that simply
counting the number of methylated loci in an individual
tumor is statistically inappropriate. Therefore, in order to
employ appropriate statistical methodologies as well as avoid
biased separation of tumors into classes based on arbitrary
counts, we employed an item response theory model which
has been shown to be the most appropriate latent trait
technique for examining this type of discrete data [42]a n d
which allows the propensity for methylation to be treated as
a continuous variable in a regression framework.
Using this approach, we observe diﬀerences in the
contribution to the underlying methylation latent trait by
the diﬀerent loci examined, an observation that would be
lost if the methylation events were simply counted and thus
considered equal. This suggests that some genes, such as
SFRP2, SFRP5,a n dCCND2, may be more informative (due
to their signiﬁcant and greater item response slopes) than
geneswithnonsigniﬁcantorsmallitemresponseslopes,such
as RASSF1A or CDKN2A.T h i si so fi n t e r e s ta sCDKN2A
(encoding P16INK4A) is often considered as a marker of
CIMP in colorectal cancer [49], but in NSCLC, silencing
of this gene appears less informative for predicting the
overall propensity for methylation. CDKN2A has also been
shown to be one of the earliest genes identiﬁed to become
hypermethylated during lung carcinogenesis, with detection
possible in epithelial cells from smokers prior to lung cancer
diagnosis [52]. Thus, alteration of this gene may be more
important in the early stages of carcinogenesis and may be
common in tumors irrespective of their overall propensity
for methylation.
We observed that tumors exhibiting more extensive LOH
at the 3p21 region showed a lower propensity for methyla-
tion. This is particularly interesting, as it is often thought
that LOH and methylation may be occurring together since
2 hits are needed to inactivate tumor suppressors. Further,
the tumor suppressor RASSF1A, which is located at 3p21,
was included in the panel of genes in our model, suggesting
that the deletion phenotype and methylation phenotype
are perhaps even less correlated than we report here. Our
results, from this examination, our previous examination of
L O Ha t3 p 2 1[ 9], and our work showing p16 deletion and
methylation to be reciprocal [14], suggest that allele loss in
the 3p21 region, beyond identifying the site of a speciﬁc
NSCLC-speciﬁc tumor suppressor gene, is a more general
marker of a propensity for genetic inactivation of tumor
suppressor genes via allelic imbalance or loss. Our data
demonstrates that tumors predisposed to this type of genetic
alteration are less likely to undergo epigenetic alterations
and vice versa. That is, our result suggests that tumor
suppressor gene silencing in NSCLCs arises either through
a preponderance of allele loss events or epigenetic silencing
events, occurring in a roughly dichotomous fashion.6 Journal of Cancer Epidemiology
Methylation propensity
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Figure 2: Model of the molecular phenotypes of NSCLC driven
by promoter hypermethylation propensity. The model depicts the
inverse relationship between epigenetic and genetic alterations and
its positive association between epigenetic propensity and growth
promoting oncogene activation.
Our model also demonstrates that KRAS mutation is
associated with a greater propensity for methylation, a result
similar to that reported in colon cancer [48, 50]. Figure 2
presents a model describing this overall relationship. The
mechanism that underlies the connection between KRAS
mutation and increased methylation propensity remains
unclear; indeed, the same can be said for the established
connection between BRAF mutation and CIMP, although
it is known that these two oncogenes operate in the same
cell signaling pathway [48, 53]. Our study as well as
previous studies cannot absolutely discern which event is
occurring ﬁrst, mutation of these genes or establishment of
greater promoter methylation, but one can speculate that
the oncogenic activation of KRAS may drive cell division,
thus increasing the possibility for alteration of promoter
methylation proﬁles. At the same time, silencing of genes
involved in DNA damage or repair through promoter
hypermethylationmayallowforthepropagationofmutation
of these oncogenes. Approaches employing model systems
with oncogenic mutation of these growth promoting genes
may help to shed light on the timing of these events and help
to answer this question.
Alimitationofthisstudywastheuseofapanelofselected
loci and a limited regional examination of deletion. Thus,
our resultsmay be indicative of gene-speciﬁc selection events
and not of the broader phenotypes that we have proposed.
To more conclusively examine, this requires genomic-level
approaches be applied for examination of the epigenetic
and genetic character within the same tumor, and new
technologies are becoming available which can allow for
this type of examination on clinical specimens. As these
technologies develop,itwillbecriticaltoemployappropriate
and rigorous statistical methods, such as those used here, to
analyze the data to allow for an understanding of the biology
driving these alterations. Our results, though, do provide an
impetus to test these hypotheses using these more genome-
wide approaches.
More broadly, these results suggest the existence of
distinct molecular pathways of tumor suppressor gene
inactivation in sporadic tumors. Classifying tumors based
on these pathways may lead to improved understanding
of the etiology of these diseases, as it may improve
the overall classiﬁcation of disease for genetic association
studies. For example, one may posit that individuals with
polymorphisms in, perhaps, genes involved in DNA repair
(particularly recombinational repair) that lead to reduced
repair capacity, may be at higher risk for the genetically
altered subclass of tumors. This improved subclassiﬁcation
also holds tremendous clinical utility as it may help to deﬁne
patients’ response to speciﬁc chemotherapeutic regimens. In
this series, we did not observe any relationship between the
methylation latent trait and overall patient survival, but we
could not examine speciﬁc subgroups based on treatment,
which could be critical for understanding this relationship.
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